|
|
| October 31, 2017: Dr. David J. Cohen and Dr. C. Michael Gibson Discuss: PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of |
Dr. David J. Cohen and Dr. C. Michael Gibson Discuss: PARTNER 2A and SAPIEN 3
Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With
Aortic Stenosis
TBD
[ Download video ] |
|
No comments have been submitted
|